Impact of type I and III interferons on respiratory superinfections due to multidrug-resistant pathogens

Journal of Infectious Diseases

Volumn 215, Issue , 2017, Pages S58-S63

  Parker, Dane ^a  

^a Columbia University ^*  (United States)

Author keywords

Influenza; Pneumonia; Staphylococcus aureus; Streptococcus pneumoniae; Superinfection; Type I interferon; Type III interferon

Indexed keywords

INFLAMMASOME; INTERFERON; INTERFERON TYPE III; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL SUPERINFECTION; COLONIZATION DENSITY; DENSITY; DISEASE ASSOCIATION; GENE ACTIVATION; HUMAN; IMMUNE RESPONSE; INFECTION SENSITIVITY; INFLAMMATION; INFLUENZA; LUNG INJURY; MICROBIOME; MULTIDRUG RESISTANCE; NASAL MICROBIOME; NONHUMAN; PHAGOCYTE; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROTEIN FUNCTION; RESPIRATORY TRACT INFECTION; SIGNAL TRANSDUCTION; STAPHYLOCOCCUS INFECTION; TH17 CELL; VIRAL CLEARANCE; BACTERIAL PNEUMONIA; BLOOD; HOST PATHOGEN INTERACTION; IMMUNOLOGY; MICROBIOLOGY; MICROFLORA; MORBIDITY; RESPIRATORY SYSTEM; RESPIRATORY TRACT DISEASE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SUPERINFECTION;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HOST-PATHOGEN INTERACTIONS; HUMANS; INFLAMMASOMES; INTERFERONS; MICROBIOTA; MORBIDITY; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, BACTERIAL; RESPIRATORY SYSTEM; RESPIRATORY TRACT DISEASES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SUPERINFECTION; TH17 CELLS;

EID: 85020374732     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw466     Document Type: Article

References (91)

1. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008;198:962-70.
2. Gill JR, Sheng ZM, Ely SF, et al. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch Pathol Lab Med 2010;134:235-43.
3. Rice TW, Rubinson L, Uyeki TM, et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med 2012;40:1487-98.
4. Shieh WJ, Blau DM, Denison AM, et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol 2010;177:166-75.
5. Blyth CC, Webb SA, Kok J, et al. The impact of bacterial and viral co-infection in severe influenza. Influenza Other Respir Viruses 2013;7:168-76.
6. Louria DB, Blumenfeld HL, Ellis JT, Kilbourne ED, Rogers DE. Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza. J Clin Invest 1959;38:213-65.
7. Robertson L, Caley JP, Moore J. Importance of Staphylococcus aureus in pneumonia in the 1957 epidemic of influenza A. Lancet 1958;2:233-6.
8. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006;12:894-9.
9. Kallen AJ, Brunkard J, Moore Z, et al. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med 2009;53:358-65.
10. McDanel JS, Perencevich EN, Storm J, et al. Increased mortality rates associated with Staphylococcus aureus and influenza co-infection, Maryland and Iowa, USA. Emerg Infect Dis 2016;22:1253-6.
11. Hasday JD, Fairchild KD, Shanholtz C. The role of fever in the infected host. Microbes Infect 2000;2:1891-04.
12. Avadhanula V, Rodriguez CA, Devincenzo JP, et al. Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species- and cell type-dependent manner. J Virol 2006;80:1629-36.
13. Loosli CG. Synergism between respiratory viruses and bacteria. Yale J Biol Med 1968;40:522-40.
14. Plotkowski MC, Puchelle E, Beck G, Jacquot J, Hannoun C. Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. Am Rev Respir Dis 1986;134:1040-4.
15. Pettigrew MM, Marks LR, Kong Y, Gent JF, Roche-Hakansson H, Hakansson AP. Dynamic changes in the Streptococcus pneumoniae transcriptome during transition from biofilm formation to invasive disease upon influenza A virus infection. Infect Immun 2014;82:4607-19.
16. Loosli CG, Stinson SF, Ryan DP, Hertweck MS, Hardy JD, Serebrin R. The destruction of type 2 pneumocytes by airborne influenza PR8-A virus; its effect on surfactant and lecithin content of the pneumonic lesions of mice. Chest 1975;67:7S-14.
17. Wang C, Armstrong SM, Sugiyama MG, et al. Influenza-induced priming and leak of human lung microvascular endothelium upon exposure to Staphylococcus aureus. Am J Respir Cell Mol Biol 2015;53:459-70.
18. Harford CG, Hara M, Technical Assistance of Alice Hamlin. Pulmonary edema in influenzal pneumonia of the mouse and the relation of fluid in the lung to the inception of pneumococcal pneumonia. J Exp Med 1950;91:245-60.
19. Levandowski RA, Gerrity TR, Garrard CS. Modifications of lung clearance mechanisms by acute influenza A infection. J Lab Clin Med 1985;106:428-32.
20. Rynda-Apple A, Robinson KM, Alcorn JF. Influenza and bacterial superinfection: illuminating the immunologic mechanisms of disease. Infect Immun 2015;83:3764-70.
21. Lietzen N, Ohman T, Rintahaka J, et al. Quantitative subcellular proteome and secretome profiling of influenza A virus-infected human primary macrophages. PLoS Pathog 2011;7:e1001340.
22. Colamussi ML, White MR, Crouch E, Hartshorn KL. Influenza A virus accelerates neutrophil apoptosis and markedly potentiates apoptotic effects of bacteria. Blood 1999;93:2395-403.
23. Smith AM, Adler FR, Ribeiro RM, et al. Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae. PLoS Pathog 2013;9:e1003238.
24. Ghoneim HE, Thomas PG, McCullers JA. Depletion of alveolar macrophages during influenza infection facilitates bacterial superinfections. J Immunol 2013;191:1250-9.
25. Nickerson CL, Jakab GJ. Pulmonary antibacterial defenses during mild and severe influenza virus infection. Infect Immun 1990;58:2809-14.
26. Didierlaurent A, Goulding J, Patel S, et al. Sustained desensitization to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. J Exp Med 2008;205:323-9.
27. McNamee LA, Harmsen AG. Both influenza-induced neutrophil dysfunction and neutrophil-independent mechanisms contribute to increased susceptibility to a secondary Streptococcus pneumoniae infection. Infect Immun 2006;74:6707-21.
28. Lee B, Robinson KM, McHugh KJ, et al. Influenza-induced type I interferon enhances susceptibility to gram-negative and gram-positive bacterial pneumonia in mice. Am J Physiol Lung Cell Mol Physiol 2015;309:L158-67.
29. Kudva A, Scheller EV, Robinson KM, et al. Influenza A inhibits Th17-mediated host defense against bacterial pneumonia in mice. J Immunol 2011;186:1666-74.
30. Guarda G, Braun M, Staehli F, et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011;34:213-23.
31. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol 2013;14:36-49.
32. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. Nat Rev Immunol 2015;15:87-103.
33. Parker D, Prince A. Type I interferon response to extracellular bacteria in the airway epithelium. Trends Immunol 2011;32:582-8.
34. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4:63-8.
35. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4:69-77.
36. Parker D, Martin FJ, Soong G, et al. Streptococcus pneumoniae DNA initiates type I interferon signaling in the respiratory tract. MBio 2011;2:e00016-11.
37. Woodward JJ, Iavarone AT, Portnoy DA. c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response. Science 2010;328:1703-5.
38. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012;12:125-35.
39. Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013;339:786-91.
40. Aubry C, Corr SC, Wienerroither S, et al. Both TLR2 and TRIF contribute to interferon-beta production during Listeria infection. PLoS One 2012;7:e33299.
41. Blazek K, Eames HL, Weiss M, et al. IFN-lambda resolves inflammation via suppression of neutrophil infiltration and IL-1beta production. J Exp Med 2015;212:845-53.
42. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008;4:e1000017.
43. Osterlund PI, Pietila TE, Veckman V, Kotenko SV, Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFNlambda) genes. J Immunol 2007;179:3434-42.
44. Levy DE, Marie IJ, Durbin JE. Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol 2011;1:476-86.
45. Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006;131:1887-98.
46. Bolen CR, Ding S, Robek MD, Kleinstein SH. Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology 2014;59:1262-72.
47. Parker D, Prince A. Staphylococcus aureus induces type I IFN signaling in dendritic cells via TLR9. J Immunol 2012;189:4040-6.
48. Koppe U, Hogner K, Doehn JM, et al. Streptococcus pneumoniae stimulates a STING- and IFN regulatory factor 3-dependent type I IFN production in macrophages, which regulates RANTES production in macrophages, cocultured alveolar epithelial cells, and mouse lungs. J Immunol 2012;188:811-7.
49. Nakamura S, Davis KM, Weiser JN. Synergistic stimulation of type I interferons during influenza virus coinfection promotes Streptococcus pneumoniae colonization in mice. J Clin Invest 2011;121:3657-65.
50. Aly R, Maibach HI, Shinefield HR, Mandel A, Strauss WG. Bacterial interference among strains of Staphylococcus aureus in man. J Infect Dis 1974;129:720-4.
51. Boris M. Bacterial interference: protection against staphylococcal disease. Bull NYAcad Med 1968;44:1212-21.
52. Light IJ, Sutherland JM, Schott JE. Control of a staphylococcal outbreak in a nursery, use of bacterial interference. JAMA 1965;193:699-704.
53. Shinefield HR, Ribble JC, Eichenwald HF, Boris M, Sutherland JM. Bacterial interference: its effect on nursery-acquired infection with Staphylococcus aureus. V. An analysis and interpretation. Am J Dis Child 1963;105:683-8.
54. Parker D, Planet PJ, Soong G, Narechania A, Prince A. Induction of type I interferon signaling determines the relative pathogenicity of Staphylococcus aureus strains. PLoS Pathog 2014;10:e1003951.
55. Martin FJ, Gomez MI, Wetzel DM, et al. Staphylococcus aureus activates type I IFN signaling in mice and humans through the Xr repeated sequences of protein A. J Clin Invest 2009;119:1931-9.
56. Iverson AR, Boyd KL, McAuley JL, Plano LR, Hart ME, McCullers JA. Influenza virus primes mice for pneumonia from Staphylococcus aureus. J Infect Dis 2011;203:880-8.
57. Lee MH, Arrecubieta C, Martin FJ, Prince A, Borczuk AC, Lowy FD. A postinfluenza model of Staphylococcus aureus pneumonia. J Infect Dis 2010;201:508-15.
58. Shahangian A, Chow EK, Tian X, et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 2009;119:1910-20.
59. Tian X, Xu F, Lung WY, et al. Poly I:C enhances susceptibility to secondary pulmonary infections by gram-positive bacteria. PLoS One 2012;7:e41879.
60. Planet PJ, Parker D, Cohen TS, et al. Lambda interferon restructures the nasal microbiome and increases susceptibility to Staphylococcus aureus superinfection. MBio 2016;7:e01939-15.
61. Kluytmans JA, Wertheim HF. Nasal carriage of Staphylococcus aureus and prevention of nosocomial infections. Infection 2005;33:3-8.
62. Peacock SJ, de Silva I, Lowy FD. What determines nasal carriage of Staphylococcus aureus? Trends Microbiol 2001;9:605-10.
63. Regev-Yochay G, Raz M, Dagan R, et al. Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings. Clin Infect Dis 2004;38:632-9.
64. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004;4:144-54.
65. Wertheim HF, Vos MC, Ott A, et al. Risk and outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers versus non-carriers. Lancet 2004;364:703-5.
66. Yu VL, Goetz A, Wagener M, et al. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 1986;315:91-6.
67. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001;344:11-6.
68. Vuononvirta J, Toivonen L, Grondahl-Yli-Hannuksela K, et al. Nasopharyngeal bacterial colonization and gene polymorphisms of mannose-binding lectin and toll-like receptors 2 and 4 in infants. PLoS One 2011;6:e26198.
69. Boelaert JR, Van Landuyt HW, Godard CA, et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. Nephrol Dial Transplant 1993;8:235-9.
70. Kluytmans J. Reduction of surgical site infections in major surgery by elimination of nasal carriage of Staphylococcus aureus. J Hosp Infect 1998;40(suppl B):S25-9.
71. Mina MJ, McCullers JA, Klugman KP. Live attenuated influenza vaccine enhances colonization of Streptococcus pneumoniae and Staphylococcus aureus in mice. MBio 2014;5:pii:e01040-13.
72. Tarabichi Y, Li K, Hu S, et al. The administration of intranasal live attenuated influenza vaccine induces changes in the nasal microbiota and nasal epithelium gene expression profiles. Microbiome 2015;3:74.
73. Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell 2014;157:1013-22.
74. Rathinam VA, Fitzgerald KA. Inflammasome complexes: emerging mechanisms and effector functions. Cell 2016;165:792-800.
75. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med 2015;21:677-87.
76. Henry T, Brotcke A, Weiss DS, Thompson LJ, Monack DM. Type I interferon signaling is required for activation of the inflammasome during Francisella infection. J Exp Med 2007;204:987-94.
77. Pothlichet J, Meunier I, Davis BK, et al. Type I IFN triggers RIG-I/TLR3/NLRP3-dependent inflammasome activation in influenza A virus infected cells. PLoS Pathog 2013;9:e1003256.
78. Fang R, Hara H, Sakai S, et al. Type I interferon signaling regulates activation of the absent in melanoma 2 inflammasome during Streptococcus pneumoniae infection. Infect Immun 2014;82:2310-7.
79. Searles S, Gauss K, Wilkison M, Hoyt TR, Dobrinen E, Meissner N. Modulation of inflammasome-mediated pulmonary immune activation by type I IFNs protects bone marrow homeostasis during systemic responses to Pneumocystis lung infection. J Immunol 2013;191:3884-95.
80. Cohen TS, Prince AS. Bacterial pathogens activate a common inflammatory pathway through IFNlambda regulation of PDCD4. PLoS Pathog 2013;9:e1003682.
81. Robinson KM, Choi SM, McHugh KJ, et al. Influenza A exacerbates Staphylococcus aureus pneumonia by attenuating IL-1beta production in mice. J Immunol 2013;191:5153-9.
82. Shepardson KM, Larson K, Morton RV, et al. Differential type I interferon signaling is a master regulator of susceptibility to postinfluenza bacterial superinfection. MBio 2016;7.
83. Li W, Moltedo B, Moran TM. Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of gammadelta T cells. J Virol 2012;86:12304-12.
84. Zhang Z, Clarke TB, Weiser JN. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 2009;119:1899-909.
85. Lin L, Ibrahim AS, Xu X, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009;5:e1000703.
86. Peck A, Mellins ED. Precarious balance: Th17 cells in host defense. Infect Immun 2010;78:32-8.
87. Cao J, Wang D, Xu F, et al. Activation of IL-27 signalling promotes development of postinfluenza pneumococcal pneumonia. EMBO Mol Med 2014;6:120-40.
88. Robinson KM, Lee B, Scheller EV, et al. The role of IL-27 in susceptibility to postinfluenza Staphylococcus aureus pneumonia. Respir Res 2015;16:10.
89. MacDonald BA, Chakravarthy KV, Davidson BA, et al. Halothane modulates the type i interferon response to influenza and minimizes the risk of secondary bacterial pneumonia through maintenance of neutrophil recruitment in an animal model. Anesthesiology 2015;123:590-602.
90. Markovic SN, Knight PR, Murasko DM. Inhibition of interferon stimulation of natural killer cell activity in mice anesthetized with halothane or isoflurane. Anesthesiology 1993;78:700-6.
91. Davis KM, Nakamura S, Weiser JN. Nod2 sensing of lysozyme-digested peptidoglycan promotes macrophage recruitment and clearance of S. pneumoniae colonization in mice. J Clin Invest 2011;121:3666-76.